A comprehensive drug evaluation of GnRHa-related drugs in breast cancer patients
Objective To evaluate the clinical application of different specifications of goserelin in breast cancer patients,to provide a basis for their rational use.Methods According to the Guidelines for Comprehensive Clinical Evaluation of Drugs,the safety,efficacy,economy,innovation,suitability and accessibility of 3.6 mg(group A),10.8 mg goserelin(group B)and 3.75 mg leuprolide(group C)in breast cancer patients were evaluated by case retrospective analysis,questionnaire,and expert demonstration.Results In terms of efficacy,the number of patients with estradiol(E2)＞5 pg·mL-1 in both group A and group B was lower than that in group C(P＜0.05).The incidence of gastrointestinal adverse reactions in groups A and B was lower than that in group C(P＜0.05),and the incidence of mild to moderate adverse reactions in group B was the lowest(P＜0.01).As to economical efficiency,group B was superior to group A and group C from average cost per day,course cost per year,frequency of administration to ratio of component effect.In terms of innovation,group B was more innovative in mechanism,and technology.But in clinical needs and reconmendation,group A had some advantage.In terms of adaptability,the comprehensive score of technical characteristics and suitability of group B was higher.All three groups had fairly good accessibility,and group B was had affordability.Conclusion Goserelin(10.8 mg)is efficacient,safe,economic,innovative,suitabile and accessibile,but the goserelin(3.6 mg)has more clinical recommendations.
goserelinbreast cancercomprehensive drug evaluation
NETL
NSTL
万方数据
